Select a medication above to begin.
Doxil
doxorubicin liposomal
Black Box Warnings .
Cardiotoxicity
myocardial damage incl. acute left ventricular failure can occur; incr. risk w/ higher cumulative dose, w/ incidence rate of 11% at cumulative dose b/w 450-550 mg/m^2; include prior anthracycline or anthracenedione use in total cumulative dosage; incr. risk if active/dormant cardiovascular dz, prior or concomitant XRT to mediastinal/pericardial area, prior anthracycline or anthracenedione tx, or concomitant cardiotoxic drug tx; cardiac toxicity may occur at lower cumulative doses w/ or w/o cardiac risk factors; assess LVEF before and regularly during and after tx
Infusion Rxns
occurred in 11% of pts w/ solid tumors, incl. serious, life-threatening and fatal cases; D/C tx for serious or life-threatening rxn; withhold tx for Grade 1, 2, or 3 rxn; s/sx may incl. flushing, SOB, facial swelling, headache, rigors, chest pain, back pain, tightness in chest or throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and/or hypotension; initiate infusion rate at 1 mg/min to minimize rxn risk
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: not interchangeable w/ doxorubicin; do not substitute on a mg to mg basis
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
ovarian CA, refractory
- [50 mg/m^2/dose IV x1 on day 1 of 28-day cycle]
Kaposi sarcoma, AIDS-assoc.
- [20 mg/m^2/dose IV x1 on day 1 of 21-day cycle]
- Info: not 1st line tx
multiple myeloma, progressive
- [30 mg/m^2/dose IV x1 on day 4 of 21-day cycle]
- Info: give up to 8 cycles; use w/ bortezomib
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [adjust dose amount]
- bilirubin >1.1: decr. usual dose, amount not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.